公开(公告)号：US20040043496A1

公开(公告)日：2004-03-04

申请号：US10463664

申请日：2003-06-16

Applicant: Berkeley HeartLab, Inc.

Inventor： H. Robert Superko

IPC: G01N033/92

CPC classification number: G01N33/92 ,  G01N2800/52

Abstract: The invention provides a method for identifying patients who will require multiple invasive cardiac procedures comprising measuring elevated LDL IVb levels in patients who have had or will have invasive heart surgery.

Abstract translation: 本发明提供了一种用于鉴定需要多次侵入性心脏手术的患者的方法，包括测量已经或将要进行侵入性心脏手术的患者的升高的LDL IVb水平。

公开(公告)号：US20030194812A1

公开(公告)日：2003-10-16

申请号：US10122081

申请日：2002-04-12

Applicant: Berkeley HeartLab, Inc.

Inventor： David Shewmake ,  Frank Ruderman ,  Christopher Boggess

IPC: G01N033/92

CPC classification number: G01N33/92 ,  G01N2800/32 ,  G01N2800/52

Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels. LDL III anullb and HDL 2b are preferred subclasses.

Abstract translation: 本发明提供了一种用于鉴定需要治疗心血管疾病的正常NCEP脂质水平的患者的方法，包括测量一种或多种LDL或HDL颗粒亚类水平并鉴定异常的LDL或HDL亚类水平。 LDL III a + b和HDL 2b是优选的亚类。

公开(公告)号：US20030235918A1

公开(公告)日：2003-12-25

申请号：US10412838

申请日：2003-04-12

Applicant: Berkeley HeartLab, Inc.

Inventor： David Shewmake ,  Frank Ruderman ,  Christopher Boggess ,  Faith Clendenen

IPC: G01N031/00

CPC classification number: G01N33/92 ,  C25B1/285 ,  G01N2800/32 ,  G01N2800/52 ,  Y10T436/104165

Abstract: The invention provides a data base of LDL, I, Ia, IIb, IIIa, IIb, IVa, IVb and HDL2a, HDL2b, HDL 3a, HDL 3b and HDL 3c together with patient data such as HDL-C, LDL-C, Apo A, ApoB, Lp(a) and patient personal data useful for treatment, diagnosing, and monitoring cardiovascular disease. The data base contains the LDL and HDL subfraction data in quantitative mg/dl values and permits deriving relationship amongst the LDL and HDL values and cardiovascular disease. Quantitative data permits more effective treatment and monitoring of cardiovascular disease. For example, quantitative differences in LDL and HDL subclass levels can determine the need for more or less aggressive treatment. The data base which includes patient events, procedures, interventions which is correlated to LDL and HD1 quantitative subclass data permits development of personalized patient treatment plans and monitoring the effectiveness of such treatment. Thus, LDL and HDL quantitative subfraction data can be used to more effectively treat and monitor cardiovascular disease. The invention, for example, provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels. LDL III a & b and HDL 2b are preferred subclasses.

Abstract translation: 本发明提供LDL，I，Ia，IIb，IIIa，IIb，IVa，IVb和HDL2a，HDL2b，HDL 3a，HDL 3b和HDL 3c的数据库以及患者数据如HDL-C，LDL-C，Apo A，ApoB，Lp（a）和患者个人资料可用于治疗，诊断和监测心血管疾病。 数据库包含定量mg / dl值中的LDL和HDL次级分数据，并允许LDL和HDL值与心血管疾病之间的关系。 定量数据可以更有效地治疗和监测心血管疾病。 例如，LDL和HDL亚类水平的定量差异可以确定对或多或少积极治疗的需要。 包括与LDL和HD1定量亚类数据相关的患者事件，程序，干预措施的数据库允许开发个性化的患者治疗计划并监测此类治疗的有效性。 因此，LDL和HDL定量分数据可用于更有效地治疗和监测心血管疾病。 例如，本发明提供了一种用于鉴定需要治疗心血管疾病的正常NCEP脂质水平的患者的方法，包括测量一种或多种LDL或HDL颗粒亚类水平并鉴定异常的LDL或HDL亚类水平。 LDL III a＆b和HDL 2b是优选的亚类。